The city of Tampa, Florida, currently has 206 active clinical trials seeking participants for Cancer research studies.
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
Recruiting
This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer, Triple Negative Breast Cancer
Exercise Prehabilitation for Locoregional Esophageal Cancer
Recruiting
The purpose of the study is to examine the feasibility and acceptability of exercise "prehabilitation" for patients preparing for esophageal cancer resection (removal).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Esophageal Cancer
Investigation of MP Pollution in the Human Respiratory System and Its Relationship to Lung Cancer
Recruiting
This project will study and characterize Microplastic (MP) burden in the lungs of patients undergoing Bronchoalveolar Levage (BAL) in thoracic clinics at Moffitt.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Lung Cancer
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
Recruiting
This is a pilot study to determine feasibility and safety of the combination of Dendritic Cell (DC1) vaccines and elacestrant in patients with hormone positive HER2 negative metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer Metastatic Breast Cancer, HER2-negative Breast Cancer
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
Recruiting
In this study, we aim to evaluate the safety and efficacy of neoadjuvant combination using intravesical romidepsin and durvalumab in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Bladder Cancer
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Recruiting
To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Senior Adult Hepatobiliary Prehab Study
Recruiting
The purpose of the study is to evaluate an exercise program for individuals with hepatobiliary cancer planning for surgery.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/05/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Hepatobiliary Cancer, Cholangiocarcinoma, Liver Metastases
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
Recruiting
The purpose of the study is to test a treatment strategy with currently approved drugs to see if it is practical to administer the available drugs in a new way that researchers hope could be more effective in treating metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Metastatic Breast Cancer
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Recruiting
This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Non-small Cell Lung Cancer
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Recruiting
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/01/2025
Locations: Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida
Conditions: Breast Cancer, Cognitive Impairments
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
Recruiting
This phase II trial studies the side effects of chemotherapy and intensity modulated radiation therapy in treating patients with low-risk HIV-associated anal cancer, and nivolumab after standard of care chemotherapy and radiation therapy in treating patients with high-risk HIV-associated anal cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: AIDS-Related Anal Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage III Anal Cancer AJCC v8, Anal Margin Squamous Cell Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Anal Non-Keratinizing Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Recruiting
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i plus hormonal therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer